“RedTail is a major leap forward in the delivery of genetic medicine via an engineered virus,” said Eric Poma, PhD, Chief Executive Officer of Calidi. “It is able to avoid immune clearance allowing ...
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for ...
Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...
lncRNAs and tumor microenvironment dynamics lncRNAs mediate the interactions between tumor cells and their surrounding microenvironment, influencing several aspects of tumor behavior. These ...
An exploratory clinical study investigating the neoadjuvant treatment of HER2-low expressing, stage II-III breast cancer with disitamab vedotin combined with penpulimab (RCVDBCIIR005). This is an ASCO ...
Advances in tissue-based technology in the past few years have created unprecedented opportunities to identify biomarkers of disease processes, especially within oncology by using multi-omics ...
Recent advances in cancer treatment highlight the potential of natural medicines to target the tumor vascular microenvironment, offering a novel strategy to inhibit tumor growth and metastasis. Unlike ...
An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results